Stocktoria
AYTU BIOPHARMA, INC AYTU
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2017-10-20
AYTU BIOPHARMA, INC financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $66.4M | $65.2M | $107.4M | $96.7M | $65.6M | $27.6M | $7.3M | $3.7M | $3.2M | $2.6M |
| Gross profit | $45.8M | $49.1M | $66.6M | $52.3M | $29.2M | $19.4M | — | — | — | — |
| R&D expense | $1.3M | $2.8M | $4.1M | $12.7M | $5.6M | $1.7M | $589,072 | $167,595 | $959,857 | $6.1M |
| SG&A expense | — | — | — | — | — | $34.8M | $18.9M | $17.7M | $17.4M | $8.5M |
| Operating income | -$7.8M | -$1.6M | -$17.1M | -$109.9M | -$58.9M | -$21.1M | -$16.8M | -$19.7M | -$20.1M | -$21.7M |
| Interest expense | — | — | — | — | — | $2.6M | $535,500 | $749,423 | $2.5M | $5.5M |
| Income tax | $437,000 | $2.1M | $0 | -$110,000 | $259,000 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$13.6M | -$15.8M | -$17.1M | -$108.8M | -$58.3M | -$13.6M | -$27.1M | -$10.2M | -$22.5M | -$28.2M |
| EPS (diluted) | — | — | $-5.11 | $-74.01 | $-3.48 | — | — | — | — | — |
| Operating cash flow | -$1.9M | -$1.4M | -$5.1M | -$28.8M | -$26.0M | -$28.4M | -$13.8M | -$15.9M | -$13.8M | -$10.7M |
| Free cash flow | -$2.2M | -$1.7M | — | — | — | -$28.4M | -$13.9M | -$16.0M | -$13.9M | -$10.9M |
| Cash & equivalents | $31.0M | $20.0M | $23.0M | $19.4M | $49.6M | $48.1M | $11.0M | $7.0M | $802,328 | $8.1M |
| Inventory | $11.4M | $12.1M | $12.0M | $10.8M | $16.3M | $10.0M | $1.4M | $1.3M | $1.3M | $524,707 |
| Total assets | $124.2M | $118.1M | $136.5M | $137.6M | $265.7M | $153.3M | $34.7M | $21.1M | $15.0M | $24.3M |
| Total liabilities | — | — | $97.1M | $93.3M | $128.1M | $58.3M | $27.6M | $7.6M | $11.0M | $14.3M |
| Shareholders' equity | $19.0M | $27.7M | $39.4M | $44.3M | $137.6M | $95.0M | $7.1M | $13.4M | $4.0M | $10.1M |
Growth · year-over-year · Revenue CAGR 43.6%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +1.8% | -39.3% | +11.1% | +47.3% | +137.5% | +277.5% | +100.0% | +13.6% | +25.7% | +878.8% |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-06-30. Facts plus Stocktoria's own computed scores — not investment advice.